Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | NA |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Primary analysis complete |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A Phase 1 placebo-controlled study extension to HVTN 073 / SAAVI 102, to evaluate the safety and immunogenicity of Novartis Sub C gp140 vaccine with MF59 adjuvant, as a boost following SAAVI DNA-C2 vaccine and SAAVI MVA-C vaccine, in HIV uninfected healthy adult participants in South Africa and the United States
Description
HVTN 073E (SAAVI 102 and HVTN 073 extension) is a Phase I clinical trial to evaluate the safety and immunogenicity of a Sub C gp140 vaccine with MF59 adjuvant boost given to participants who received SAAVI DNA-C2 and SAAVI MVA-C in HVTN 073.
Sign in to see full information about this study and to download study data.
Products
Product info coming soon!Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.